Company intelligence / Profile preview

AdeTherapeutics

Saskatoon, Saskatchewan, Canada

Ownership: Private
Development stage: Other

Overview

AdeTherapeutics developed novel small molecule therapies for surgical adhesion prevention and scar tissue reduction. Their lead product achieved approval for keloid in at least one country, with other pipeline assets discontinued or pending. The company collaborated extensively and out-licensed technology to Temple Therapeutics.

Therapeutic areas: NeurologyDermatologyOther
Modalities: Small molecule
Industry: Biotech

Partnerships

DSMDalton Pharma ServicesNumoda CorporationRoyal BiomedicalTemple Therapeutics (licensee)

Beyond the preview

Go deeper on AdeTherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdeTherapeutics.

Explore the full profile